Hyperfine (HYPR) Proxy Filing summary

Executive summary

• Achieved significant progress in financial profile and business strategy, including revenue growth, margin expansion, and reduced cash burn.

• Raised $6.0 million through a direct offering, extending cash runway to end of 2026.

• Expanded commercial foundation with new software launches, clinical recognition, and global market entry.

• Plans for 2025 include two major software releases, targeting neurology offices, and further international expansion, including anticipated entry into India.

• Annual meeting to be held virtually, with voting and Q&A available online.

Voting matters and shareholder proposals

• Election of six directors for one-year terms expiring in 2026.

• Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2025.

• Board recommends approval of all proposals.

• Shareholders may submit proposals for the 2026 meeting by specified deadlines.

Board of directors and corporate governance

• Board consists of six members, all nominated for re-election.

• Three directors are independent under Nasdaq rules.

• Company qualifies as a "controlled company" under Nasdaq due to majority voting power held by Dr. Rothberg.

• Board committees: audit, compensation, and nominating/corporate governance, each with defined charters and independent members.

• Board leadership structure separates CEO and chairperson roles.